Individual COVID‐19 disease trajectories revealed by plasma proteomics. Issue 8 (14th July 2021)

• Record Type: Journal Article
• Authors: Memon, Danish; Barrio‐Hernandez, Inigo; Beltrao, Pedro
• Is Part Of: EMBO molecular medicine. Volume 13:Issue 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-07-14
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.202114532
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract : Since the start of 2020, the world has been upended by the pandemic caused by the severe acute respiratory coronavirus type 2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19). It has not only led to a tragic loss of life and terrible economic costs but has also been met with an unprecedented response of the scientific and medical communities. In an effort to better understand this viral infection, scientists around the world generated the largest surge in research in documented history for any topic (Lever & Altman, 2021). A part of this work has included the need to better understand the impact of the virus on human proteins—the key machinery of the cell—and human physiology. In their recent study, Geyer and colleagues (Geyer et al, 2021) analyzed a total of 720 proteomes from longitudinal serum samples of 31 hospitalized COVID‐19 patients and control individuals with COVID‐19‐like symptoms but not infected with SARS‐CoV‐2, providing a comprehensive characterization of the plasma proteome changes along the time course of infection. Abstract : D. Memon, I. Barrio‐Hernandez, and P. Beltrao discuss the study by Geyer et al (in this issue of EMBO Mol Med ) that analyzes the plasma proteome changes for a longitudinal cohort of COVID‐19 patients.